Several biotechs pushed into or expanded public markets, providing fresh capital for clinical de-risking and pipeline buildouts. Attovia priced an upsized IPO reported at roughly $289–$298 million to fund Phase II development for ATTO-1310, an engineered biologic built to block IL-31 for chronic pruritic diseases. Braveheart Bio also priced an upsized IPO of $382.5 million to advance BHB-1893, an oral cardiac myosin inhibitor in hypertrophic cardiomyopathy toward Phase 3 in obstructive and non-obstructive subtypes. These raises are part of a denser IPO calendar for drugmakers seeking Phase II-to-Phase III momentum. Separately, Expedition Therapeutics closed a $115 million Series B led by General Atlantic to progress its COPD candidate into mid-stage clinical work. The funding also supports pipeline expansion and operational buildout. Overall, the funding mix shows continued investor appetite for assets with clear mechanistic differentiation and scalable development plans, alongside platform-driven narratives in immunology and chronic disease.